Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Aug 5;17(8):100943.
doi: 10.1016/j.waojou.2024.100943. eCollection 2024 Aug.

Does angioedema in patients with chronic spontaneous urticaria impact response to omalizumab?

Thomas B Casale  1 , Benjamin Trzaskoma  2 , Michael Holden  2 , Jonathan A Bernstein  3 , Marcus Maurer  4   5
Affiliations

Does angioedema in patients with chronic spontaneous urticaria impact response to omalizumab?

Thomas B Casale et al. World Allergy Organ J. .

Abstract

The presence of angioedema, or deep skin swelling, in addition to hives (wheals) in patients with chronic spontaneous urticaria (CSU) can complicate disease management. There is evidence that omalizumab is effective for patients with CSU with angioedema, but the time to a clinically meaningful response has not been assessed. This post hoc analysis examined data from the phase 3, randomized, double-blind ASTERIA I and ASTERIA II studies: patients with CSU with hives were grouped by presence (n = 216) or absence of angioedema (n = 265) at baseline. The time to minimally important difference (MID, change from baseline of ≥11 points) in weekly Urticaria Activity Score (UAS7) was analyzed using Kaplan-Meier analyses. Median time to MID for omalizumab 300 mg was similar in patients with and without angioedema. Median time to MID for omalizumab 150 mg was similar to 300 mg for patients without angioedema, and was longer for patients with angioedema. Therefore, the response to omalizumab for patients with CSU with angioedema was dose dependent. We recommend that the best approach for clinicians, in line with guidelines, would be initial administration of omalizumab 300 mg every 4 weeks for all patients.

Clinical trials registration: Clinicaltrials.gov NCT01287117 (registered 27 January 2011) and NCT01292473 (registered 7 February 2011).

Keywords: Angioedema; Chronic spontaneous urticaria; Omalizumab.

PubMed Disclaimer

Conflict of interest statement

Thomas Casale is a consultant and speaker bureau member for Genentech, Inc.; consultant for Novartis Pharmaceuticals Corporation. Benjamin Trzaskoma and Michael Holden are employees of Genentech, Inc.; stockholders in Roche. Jonathan Bernstein is a consultant and PI for Genentech, Inc., Novartis, Amgen, GSK, Sanofi-Regeneron, AstraZeneca, Celldex, Allakos, Escient, Teva, Takeda/Shire, CSL Behring, Biocryst, Kalvista, Ionis, Biomarin, Pharming, Jasper. Marcus Maurer is a speaker and/or advisor for and/or has received research funding from Allakos, Alexion, Almirall, Alvotech, Amgen, Aquestive, Arcensus, argenX, AstraZeneca, Astria, BioCryst, Blueprint, Celldex, Celltrion, Clinuvel, Cogent, CSL Behring, Escient, Evommune, Excellergy, Genentech, GSK, Incyte, Jasper, Kashiv, Kalvista, Kyowa Kirin, Leo Pharma, Lilly, Menarini, Mitsubishi Tanabe Pharma, Moxie, Noucor, Novartis, Orion Biotechnology, Pharvaris, Resonance Medicine, Sanofi/Regeneron, Santa Ana Bio, Septerna, Servier, Takeda, Teva, Third HarmonicBio, Valenza Bio, Vitalli Bio, Yuhan Corporation, Zurabio.

Figures

Fig. 1
Fig. 1
Median time to minimally important difference (MID; change from baseline of ≥11 points) in weekly Urticaria Activity Score (UAS7) for patients with or without angioedema at baseline
See this image and copyright information in PMC

References

    1. Sussman G., Abuzakouk M., Bérard F., et al. Angioedema in chronic spontaneous urticaria is underdiagnosed and has a substantial impact: analyses from ASSURE-CSU. Allergy. 2018;73:1724–1734. - PMC - PubMed
    1. Zazzali J.L., Kaplan A., Maurer M., et al. Angioedema in the omalizumab chronic idiopathic/spontaneous urticaria pivotal studies. Ann Allergy Asthma Immunol. 2016;117:370–377.e1. - PubMed
    1. Buttgereit T., Vera C., Aulenbacher F., et al. Patients with chronic spontaneous urticaria who have wheals, angioedema, or both, differ demographically, clinically, and in response to treatment - results from CURE. J Allergy Clin Immunol Pract. 2023;11:3515–3525.e4. - PubMed
    1. Staubach P., Metz M., Chapman-Rothe N., et al. Effect of omalizumab on angioedema in H1-antihistamine-resistant chronic spontaneous urticaria patients: results from X-ACT, a randomized controlled trial. Allergy. 2016;71:1135–1144. - PubMed
    1. Maurer M., Rosén K., Hsieh H.J. Omalizumab for chronic urticaria. N Engl J Med. 2013;368:2530. - PubMed

Associated data

LinkOut - more resources